Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Certara Supports Eleven Recent Drug Approvals through Model-based Drug Development

Pharsight Consulting Services applies quantitative models to decision making ST. LOUIS, MO – February 13, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, published a new white paper that summarizes its involvement and support of eleven drug approvals over the past […]

More Info

Model-based Meta-analysis of the HbA1c Lowering Effect of PF-04971729, a Sodium Glucose Co-transporter-2 Inhibitor (SGLT2i), In Comparison to Other SGLT2i and Anti-diabetic Agents (ADA)

PF-04971729 is a potent, selective SGLT2i in development for treatment of type 2 diabetes mellitus (T2DM). Since there is growing recognition of the need for comparative effectiveness of various ADA, a model was developed to quantify time course of dose vs HbA1c response of PF-04971729 relative to other ADA including SGLT2i, DPP4 inhibitors (DPP4i), GLP-1 […]

Author(s): Jaap Mandema, Kevin Sweeney, Steven Terra, Vaishali Sahasrabudhe
Year: 2012
More Info

Model-based Meta-analysis of the Effect on Body Weight of PF-04971729, a Sodium Glucose Co-transporter-2 Inhibitor (SGLT2i), in Comparison to Other SGLT2i and Anti-diabetic Agents (ADA)

PF-04971729 is a potent, selective SGLT2i in development for treatment of type 2 diabetes mellitus (T2DM). Since there is growing recognition of the need for comparative effectiveness of various ADA, a model was developed to quantify the time course of dose vs body weight change for PF-04971729 relative to other ADA including SGLT2i, DPP4 inhibitors […]

Author(s): Jaap Mandema, Kevin Sweeney, Steven Terra, Vaishali Sahasrabudhe
Year: 2012
More Info